Clinical trial NCT00097851: Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)
Official title: Phase II Trial of Docetaxel With PI-88 in Patients With Advanced Non-Small-Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: second-line
combination
chemotherapy
anti-angiogenic
Lead sponsor: Cellxpert Biotechnology Corp.
Sponsor class: INDUSTRY
Collaborators: name: Medigen Biotechnology Corporation
First posted: 2004-12-01
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: PI-88 is a new experimental drug that inhibits tumour growth by reducing the formation of new blood vessels into tumours. Docetaxel is a standard second-line treatment offered to patients with non-small-cell lung cancer who haven't responded to first-line therapies (platinum-based drugs or radiotherapy). Of this group of patients, only 20% remain progression-free 6 months after starting docetaxel treatment. The PR88202 study has been designed to compare two different cancer treatments (docetaxel only, and docetaxel plus PI-88) and to work out which is more effective against the cancer. It is hoped that the combination of PI-88 with docetaxel will allow patients to extend the time it takes for their disease to progress, and also to improve their quality of life.

Detailed description: PR88202 is an open-label randomized study. In the initial phase of the study, patients will be randomized to receive weekly docetaxel alone, or PI-88 in combination with weekly docetaxel. Both groups will receive docetaxel (30 mg/m2), administered by intravenous infusion on days 1, 8 and 15 of a 28-day cycle. The second group only will receive PI-88 (250 mg/day) in addition to docetaxel; PI-88 will be administered by subcutaneous injection on days 1-4, 8-11 and 15-18 of each cycle. The primary efficacy endpoint is the non-progression rate at 6 months. In the extension phase of the study, patients in the combination arm who have stable disease or an objective response after up to six treatment cycles will remain on PI-88 alone as maintenance therapy. Patients who initially receive docetaxel alone and who have disease progression or unacceptable toxicity before the completion of six cycles will be eligible to receive PI-88 alone as third-line therapy.

Eligibility criteria: Inclusion Criteria:

* histologically or cytologically confirmed stage IIIb or IV NSCLC that has progressed during or after first-line treatment
* measurable disease by spiral CT chest scan, as defined in RECIST criteria
* performance status 0-1 (ECOG)
* life expectancy at least 2 months
* adequate hemopoietic, renal and hepatic function

Exclusion Criteria:

* current symptomatic central nervous system (CNS) involvement
* prior or co-existent malignancies
* significant non-malignant disease
* acute or chronic gastrointestinal (GI) bleeding in last two years
* inflammatory bowel disease
* abnormal bleeding tendency
* patients at risk of bleeding due to open wounds or planned surgery
* clinically significant hemoptysis within the past 4 weeks
* bilirubin \> upper limit of normal (ULN)
* ALT and AST \> 2.5 times ULN, or \> 1.5 times ULN if alkaline phosphatase \> 2.5 times ULN
* alkaline phosphatase \> 5 times ULN, unless patient has bone metastases
* myocardial infarction, stroke or congestive heart failure within last 3 months
* prior treatment with docetaxel
* concomitant treatment with aspirin (\>100 mg/day), NSAIDs (except selective COX-2 inhibitors, warfarin (\>1 mg/day), heparin, LMWH, anti-platelet drugs, CYP3A4 inhibitors
* women who are pregnant or breast-feeding
* women of child-bearing potential not using adequate contraception
* history of allergy and/or hypersensitivity to anti-coagulants or thrombolytic agents, especially heparin
* history of immune-mediated thrombocytopenia, thrombotic thrombocytopenic purpura or other platelet disease
* allergy to polysorbate 80 (component of Taxotere®)
* uncontrolled or serious infection in last 4 weeks

Primary outcomes:
measure: Progression-free survival
Secondary outcomes:
measure: Time to progression
measure: Response rate
measure: Quality of life
measure: Overall survival
Other outcomes:
Locations:
city: Camperdown
country: Australia
facility: Sydney Cancer Centre, Royal Prince Alfred Hospital
state: New South Wales
city: Hornsby
country: Australia
facility: Sydney Haematology and Oncology Clinics
state: New South Wales
city: Randwick
country: Australia
facility: Prince of Wales Hospital
state: New South Wales
city: St Leonards
country: Australia
facility: Royal North Shore Hospital
state: New South Wales
city: Waratah
country: Australia
facility: Newcastle Mater Misericordiae Hospital
state: New South Wales
city: Chermside
country: Australia
facility: Prince Charles Hospital
state: Queensland
city: Nambour
country: Australia
facility: Nambour General Hospital
state: Queensland
city: South Brisbane
country: Australia
facility: Mater Hospital
state: Queensland
city: Woolloongabba
country: Australia
facility: Princess Alexandra Hospital
state: Queensland
city: Woodville
country: Australia
facility: The Queen Elizabeth Hospital
state: South Australia
city: Prahran
country: Australia
facility: The Alfred Hospital
state: Victoria
city: Wodonga
country: Australia
facility: Border Medical Oncology
state: Victoria
city: Nedlands
country: Australia
facility: Sir Charles Gairdner Hospital
state: Western Australia
Study officials:
affiliation: Royal North Shore Hospital
name: Nick Pavlakis, MD
role: STUDY_CHAIR
affiliation: Austin and Repatriation Hospital
name: Paul Mitchell, MD
role: STUDY_DIRECTOR
References: